Derma Sciences Inc. (NASDAQ:DSCI) dropped 2.1% on Friday . The company traded as low as $4.67 and last traded at $4.74, with a volume of 112,946 shares trading hands. The stock had previously closed at $4.84.

DSCI has been the topic of a number of recent analyst reports. Zacks Investment Research cut Derma Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. TheStreet raised Derma Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, August 9th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $7.35.

The company has a 50 day moving average of $4.80 and a 200 day moving average of $3.90. The stock’s market cap is $133.60 million.

Derma Sciences (NASDAQ:DSCI) last announced its quarterly earnings data on Tuesday, August 9th. The company reported $0.08 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.16. The company had revenue of $22.20 million for the quarter, compared to analyst estimates of $22.40 million. Equities analysts expect that Derma Sciences Inc. will post ($0.04) EPS for the current year.

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.